Will a change to the U.S. carried interest loophole have a material impact on how capital is invested into startups?
Malnutrition is very common among hospitalized patients in the U.S., and its coded prevalence is increasing. Amid this problem lies an opportunity to optimize the overall quality of patient care, impr
Fifty Years, a six-year-old, San Francisco-based outfit with a portfolio that’s already rife with mostly deep tech companies — many with a good story to tell about how they can have an imp
You might have thought that with more than 300 companies joining this year’s winter batch of Y Combinator, the investor interest might have thinned. Well, it’s 2021 and investors are hopping aroun
Not every company’s founders find themselves on a first-name basis with the local bomb squad, but then again not every company is Noya Labs, which wants to turn the roughly 2 million cooling tow
From a young age, Will Bruey, the co-founder and chief executive of Varda Space Industries, was fascinated with space and running his own business. So when the former SpaceX engineer was tapped by Del
It’s too soon to know who will win the U.S. election tomorrow. Tomorrow may even be too soon to know who wins the election. But it’s always a good time to talk with investors about how the
Daniel Arlow has spent the last eighteen years studying genomics and synthetic biology. The arc of his career has taken the first-time founder of the new startup Ansa Biotechnologies from MIT to the f
There’s a growing wave of commercial activity from companies that are creating products using new biological engineering technologies. Perhaps the most public (and tastiest) example of the promi